One Health Company, a bio company bridging the gap between canine and human cancer therapeutics, announced $10M in new financing from Polaris Partners and Borealis Ventures, with participation from existing investors Andreessen Horowitz, Lerer Hippeau, Y-Combinator, and Tau Ventures.

The One Health Company is the first to bring the latest advances in human oncology - individualized, precision medicine - to dogs with cancer. The firm is a mission company that delivers the most sophisticated diagnostics and create a tailored treatment plan for each dog. The firm's flagship product, FidoCure, leverages what has been approved for human use, with additional data specific to canine cancer.